List of Peer Reviewed Papers, Abstracts & Posters

1. Fernández-Moreno M, Hermida-Gómez T, Larkins N, Reynolds A, Blanco FJ. Anti-Inflammatory Activity of APPA (Apocynin and Paeonol) in Human Articular Chondrocytes. Pharmaceuticals. 2024; 17(1):118. https://doi.org/10.3390/ph17010118

2. Fernandez-Moreno M, Hermida Gómez T, Larkins N, Reynolds A, Blanco-Garcia F. Effect of APPA (combination of apocynin and paeonol) compound on cellular senescence using human articular chondrocytes. Osteoarthritis and Cartilage. 2023;31 (Suppl 1) Abstract 447:S401

3. Bihlet AR, Byrjalsen I, Andersen JR, Metnik A, Reynolds A, Larkins N, et al. POS0180 The efficacy and safety of a fixed-dose combination of apocynin and paeonol in symptomatic knee oa: A double-blind, randomized, placebo-controlled clinical trial. Annals of the rheumatic diseases. 2022;81(Suppl 1):321- Abstract PSO0180

4. Fernandez-Moreno M, Larkins N, Reynolds A, Hermida Gómez T, Blanco FJ. APPA (apocynin and paeonol) reduces ROS production and senescence in human articular chondrocytes. Annals of the Rheumatic Diseases. 2021;80(Suppl 1):1051 Abstract AB0036.

5. Thudium CS, Bay-Jensen AC, Gantzel T, Dziegiel M, Larkins N, Reynolds A. Characterizing the effect of APPA on tissue turnover in cartilage and bonetissue cultures. Osteoarthritis and Cartilage. 2021;29 (Supplement1):SS152 Abstract 83

6. Fernandez-Moreno M, Larkins N, Reynolds A, Hermida-Gomez T, Blanco FJ. Biological effect of APPA (Apocynin and Paeonol) in human articular chondrocytes. Osteoarthritis and Cartilage. 2021;29 (supplement1):S358 Abstract 432.

7. Larkins N. Efficacy and safety of the combination of apocynin and paeonol (APPA) in patients with osteoarthritis: An uncontrolled patient case series. Annals of the rheumatic diseases. 2020;79 (Suppl 1):1738 Abstract AB0872.

8. Cross AL, Hawkes J, Wright HL, Moots RJ, Edwards SW. APPA (apocynin and paeonol) modulates pathological aspects of human neutrophil function, without supressing antimicrobial ability, and inhibits TNFα expression and signalling. Inflammopharmacology. 2020;28(5):1223-35.

9. Cross AL, Hawkes JJ, Wright HL, Moots RJ, Edwards SW. APPA Inhibits neutrophil pro-inflammatory functions without impairing host defence: is this a potential new therapy for arthritis? Rheumatology (Oxford). 2019;58 Supplement 3:46, Abstract 014.

10. Cross A, Hawkes J, Wright H, Larkins N, Edwards S, Moots R. APPA, a potential new therapy for osteoarthritis, inhibits neutrophil pro-inflammatory functions without impairing host defence. Osteoarthritis and Cartilage. 2019;27 (Suppl 1):S189 – S90.

11. Larkins N, King C. Effectiveness of apocynin-paeonol (APPA) for the management of osteoarthritis in dogs: comparisons with placebo and meloxicam in client-owned dogs. Matters. 2017;10.19185/matters.201608000001.

12. Larkins N, King C. APPA compared against meloxicam in canine OA. Osteoarthritis and Cartilage. 2017;25:S176.

13. Cross A, Hawkes J, Moots R, Larkins N. Effects of APPA on human neurophil function. Osteoarthritis and Cartilage. 2016;24:S335-S6 Abstract 548.

14. Glasson S, Bendele A, N L. APPA provides disease modification in preclinical osteoarthritis. Planta Med. 2012;78:PI215.

15. Glasson S, Larkins N. APPA provides symptom relief in clinical canine osteoarthritis. Osteoarthritis and Cartilage. 2012;20 (Suppl 1):S287 Abstract 572.

16. Glasson S, Bendele A, Larkins N. APPA provides disease modification in preclinical osteoarthritis. Osteoarthritis and Cartilage. 2012;20:S72 -S3 Abstract 132